Featured Question

How do the latest, long-acting treatments for schizophrenia compare in terms of their indications and their efficacy and safety profiles? And what considerations should influence selection of one agent over another?

See The Answer

Get the latest
science delivered
to your inbox

Answers in CME updates are
available in YOUR specialty.

Sign-up Now!

Featured Activities


Practical Considerations in the Management of Patients With Ulcerative Colitis

Course Director
William J. Sandborn, MD
University of California San Diego
La Jolla, California


Current and Emerging Imaging Techniques in Multiple Sclerosis: Where Are We Now and Where Are We Going?

Course Director
Robert Naismith, MD
Washington University
School of Medicine
St. Louis, Missouri


The Expanding Role of Biologic Therapies for Ulcerative Colitis: Assessing the State of the Science and Implications for Practice

Course Director
William J. Sandborn, MD
University of California San Diego
La Jolla, California


Practical Considerations for the Management of Alzheimer’s Disease: Tools for Recognition of Early Disease and Nuances of Individualized Treatment Selection

Course Director
Anton P. Porsteinsson, MD
University of Rochester
School of Medicine and Dentistry
Rochester, New York


Q&A: Assessing the Evolving Role of Angiogenesis-Targeting Agents in the Treatment of Gynecologic Cancers

Course Director
Maurie Markman, MD
Cancer Treatment Centers of America
Drexel University School of Medicine
Philadelphia, Pennsylvania


Therapeutic Advances in Alzheimer’s Disease: Improving Adherence, Early Treatment Initiation, and Disease-Modifying Agents

Course Director
Gary W. Small, MD
David Geffen School of
Medicine at UCLA
Semel Institute for Neuroscience and Human Behavior
Stewart & Lynda Resnick Neuropsychiatric Hospital
Los Angeles, California


Challenging Cases in Multiple Sclerosis

Course Director
Aaron E. Miller, MD
Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai School of Medicine
New York, New York